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samples of 150 consecutive eligible patients each were enrolled into the study in the pre-and post-guideline periods. In the pre-guideline sample, the median age was 37.3 (+/-17) years and 67% were men. In the post-guideline period, the median age was 40.2 (+/-16.2) years and 73% were men.
Study design
This was a retrospective comparative study where the study groups were not evaluated concurrently but in two distinct timeframes. It was carried out in a single centre (the tertiary care teaching hospital). The patients were allocated to the study groups according to when they were enrolled in the study. The patients were not followed after hospital discharge.
Analysis of effectiveness
All of the patients included in the initial study sample were accounted for in the effectiveness analysis. The primary health outcome used in the analysis was the frequency of major GI bleeding (i.e. number of patients). This was defined as a difference of at least 2 g/dL between two consecutive haemoglobin values in conjunction with clinically apparent coffee-ground emesis, haematemesis, melena, or haematochezia. The number of patients prescribed stress ulcer prophylaxis and meeting (or not meeting) guideline criteria in the post-guideline period was also evaluated. The study groups were comparable at baseline in terms of their demographic and clinical characteristics.
Effectiveness results
The frequency of major GI bleeding was 0.7% (only 1 patient) in the pre-guideline group and 0% (no patients) in the post-guideline group. The difference was not statistically significant.
The total number of patients prescribed stress ulcer prophylaxis was 105 (70%) in the pre-guideline period and 39 (26%) in the post-guideline period, (p<0.0001).
Of the 39 patients who were prescribed stress ulcer prophylaxis in the post-guideline group, only 24 met the guideline criteria. For the 15 that did not meet the guideline criteria, the pharmacist made a recommendation to the surgery house staff to discontinue therapy in 13. However, only 9 patients actually discontinued the therapy.
During the course of the study, pharmacist recommendations also resulted in therapy being discontinued in 14 of the 17 patients who were identified as no longer requiring therapy.
Clinical conclusions
The effectiveness evidence showed that the guidelines were useful in identifying the patients who benefited from stress ulcer prophylaxis, without increasing the frequency of major GI bleeding.
Measure of benefits used in the economic analysis
No summary benefit measure was used in the economic evaluation. A cost-consequences analysis was therefore carried out.
Direct costs
Discounting was not relevant because the costs were incurred in a short time period. The unit costs were not analysed separately from the quantities of resources used. The health services in the economic evaluation were the drugs used for the trauma stress ulcer prophylaxis and administration-related resources, such as syringes and minibags. Pharmacy preparation and dispensing costs were not included in the analysis. The cost/resource boundary adopted in the study was not explicitly stated. The unit costs were estimated on the basis of the average wholesale prices for drugs and other devices. Resource consumption was derived using individualised data coming from the sample of patients involved in the effectiveness study from November 15, 1997 to January 23, 1998 (pre-guideline group) or from February 22 to April 19, 1998 (post-guideline group). The calculation was based on the number of patients prescribed
